Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 10, 2016 4:01 PM ESTSEATTLE and SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2015.
Corporate Update and Recent Highlights
New positive data support continued development of Immune Designs wholly-owned immuno-oncology product candidates.
LV305, the novel vector component of CMB305 that delivers NY-ESO-1 RNA specifically to dendritic cells in vivo, has achieved full patient enrollment in the Phase 1... More